Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients ... ( SCOTTSDALE Ariz. Aug. 20 /- MedPr...)

Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients on Tysabri

Date:8/20/2008

SCOTTSDALE, Ariz., Aug. 20 /PRNewswire/ -- MedPredict, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for multiple sclerosis (MS) therapies.

Biogen/Elan's Tysabri has been under scrutiny due to two additional reported cases of PML, a rare and potentially fatal brain disease associated with use of the drug. MedPredict recently convened an expert panel of neurologists to assess the significance of the PML cases, and the effect on prescribing and development of new potent immunosurveillants.

"Nobody at the Thought Leader level was surprised that there were more new (PML) events," according to Jeff Berk, MedPredict's president. "At the time of the reinstatement of the US license for Tysabri, the FDA Advisory Committee stated that they expected there to be more events. Our panel discusses whether that sentiment will translate to community-based neurologists."

The report also updates progress on other approaches to treatment of MS, including:

-- New interferons, integrin inhibitors, B-cell inhibitors, S1Ps, fumarates, neuroprotection/neuroregeneration.

-- The potential for vaccine or MAb approaches for the treatment or prevention of multiple sclerosis.

-- Which therapeutics in development to provide symptomatic benefits in MS are the most likely winners.

MedPredict's analysis also provides guidance for clinical trial design in MS. "There have been a number of high-profile failed trials, both in relapsing-remitting and in progressive MS," said Dr. Berk. "The panel talks about strategies for improving the odds of success through better designs and better metrics."

Companies and partnerships discussed in this report include: Acorda, Amgen/Epix, Artielle ImmunoTherapeutics, Avanir, BaroFold, Bayhill, Bayer-Schering, Bayer-Schering/Genzyme, Biogen, Biogen/Ela
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Duff & Phelps Acquires Lumin Expert Group To Build Global Intellectual Property Practice
2. PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory
3. Leading AIDS Experts Urge Greater Focus on Behavior-Change Programs to Prevent HIV
4. Cepheid Introduces GeneXpert(R) Infinity-48 System at 2008 American Association of Clinical Chemistry Meeting
5. Informex365.com is Launched for Manufacturers in Search of Chemical Reactions Expertise
6. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
7. Online Career Tool Offers Live Expert Advice Component
8. Expert Consensus Panel Recommendation for Incorporating Lp-PLA2 Testing into Cardiovascular Disease Risk Assessment Guidelines
9. PAREXEL Experts to Address Key Industry Topics at the Drug Information Association 44th Annual Meeting
10. Experts From The Peer Group Provide Training on Dialogue-Based Influence at the SPBT Annual Conference
11. PAREXEL Product Development and Regulatory Experts to Attend the 2008 BIO International Convention

Post Your Comments:

Expert Neurology Panel Weighs Impact of New Reports of PML in Multiple Sclerosis Patients ...( SCOTTSDALE Ariz. Aug. 20 /- MedPr...)